Utilization of integrative medicine differs by age among pediatric oncology patients.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
06 2019
Historique:
received: 12 11 2018
revised: 15 01 2019
accepted: 16 01 2019
pubmed: 2 2 2019
medline: 19 12 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

Coping with symptoms related to cancer treatment is challenging for pediatric patients with cancer and their caregivers. Additionally, caring for pediatric patients requires specialized expertise to incorporate age-appropriate interventions to improve outcomes. Despite the increase in pediatric inpatient integrative medicine (IM) therapies, there is a paucity of knowledge about whether the utilization of IM therapies differs by patient age. We conducted a retrospective analysis on IM utilization among pediatric inpatients between 2008 and 2016 in a tertiary urban cancer center using electronic medical records. Multivariable logistic regression models examined the relationship between age and specific type of IM utilization, adjusting for specific demographic factors. Between 2008 and 2016, the pediatric inpatient IM service had 20 686 visits and treated 1877 unique patients. A significant age difference (P < 0.001) by modality was noted: dance therapy (mean age ± standard deviation: 5.9 ± 5.3 years), music therapy (8.0±7.0 years), mind-body therapies (13.0 ± 7.7 years), massage (14.5 ± 7.8 years), and acupuncture (20.0 ± 7.9 years). In multivariable analysis, the association between age and use of specific IM therapies remained significant (P < 0.001 for all). Specific types of inpatient IM therapy usage significantly differed by the age of pediatric patients with cancer; therefore, designing and providing age-appropriate IM interventions with consideration for developmental stage are needed to ensure that the most appropriate and effective therapies are provided to children with cancer.

Identifiants

pubmed: 30706689
doi: 10.1002/pbc.27639
pmc: PMC6866674
mid: NIHMS1052533
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e27639

Subventions

Organisme : NCATS NIH HHS
ID : KL2TR002385
Pays : United States
Organisme : NCI NIH HHS
ID : P30-CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002385
Pays : United States

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S829-33
pubmed: 26700928
Evid Based Complement Alternat Med. 2007 Sep;4(3):367-74
pubmed: 17965769
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
J Clin Oncol. 2010 Mar 1;28(7):1154-60
pubmed: 20100963
Cancer Pract. 1999 Jan-Feb;7(1):34-42
pubmed: 9893002
Pediatrics. 2012 Jun;129 Suppl 3:S153-60
pubmed: 22661762
Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S585-618
pubmed: 26700919
Clin Psychol Rev. 2002 Jun;22(5):753-86
pubmed: 12113204
Psychooncology. 2002 Sep-Oct;11(5):379-88
pubmed: 12228871
J Clin Oncol. 2015 Nov 1;33(31):3615-20
pubmed: 26304905
Pediatr Phys Ther. 2008 Spring;20(1):66-80
pubmed: 18300936
Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S419-24
pubmed: 26397836
J Natl Cancer Inst. 2001 Jun 6;93(11):810-23
pubmed: 11390531
Support Care Cancer. 2006 Feb;14(2):172-6
pubmed: 16021478
Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S694-723
pubmed: 26700922
J Pediatr Psychol. 2003 Oct-Nov;28(7):447-52
pubmed: 12968036
JAMA. 1996 Jan 24-31;275(4):267-8
pubmed: 8544252
Evid Based Complement Alternat Med. 2007 Mar;4(1):23-34
pubmed: 17342238
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Curr Opin Pediatr. 2006 Oct;18(5):558-62
pubmed: 16969172
J Clin Oncol. 2015 Sep 20;33(27):2935-7
pubmed: 26304907
Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S632-83
pubmed: 26700921
Eur J Cancer. 2004 Sep;40(14):2041-6
pubmed: 15341976
Cancer. 2014 Dec 1;120(23):3744-51
pubmed: 25077452
Pediatrics. 2010 Apr;125(4):768-76
pubmed: 20308209
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Pediatr Oncol Nurs. 2013 Nov-Dec;30(6):320-32
pubmed: 24371260
J Pediatr Hematol Oncol. 2013 May;35(4):281-8
pubmed: 23612379
Pediatr Blood Cancer. 2017 Jul;64(7):null
pubmed: 28176457
Curr Treat Options Oncol. 2008 Jun;9(2-3):127-34
pubmed: 18704692

Auteurs

Hyeongjun Yun (H)

Memorial Sloan Kettering Cancer Center, New York, New York.

Sally A D Romero (SAD)

Memorial Sloan Kettering Cancer Center, New York, New York.

Benjamin Record (B)

Memorial Sloan Kettering Cancer Center, New York, New York.

Julia Kearney (J)

Memorial Sloan Kettering Cancer Center, New York, New York.

Nirupa Jaya Raghunathan (NJ)

Memorial Sloan Kettering Cancer Center, New York, New York.

Stephen Sands (S)

Memorial Sloan Kettering Cancer Center, New York, New York.

Jun J Mao (JJ)

Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH